Sarepta Therapeutics’ (SRPT) “Outperform” Rating Reaffirmed at Cowen and Company
Cowen and Company restated their outperform rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a research note published on Wednesday morning. The firm currently has a $64.00 target price on the stock.
Other analysts also recently issued research reports about the stock. Oppenheimer Holdings Inc. reaffirmed a buy rating and set a $60.00 price target on shares of Sarepta Therapeutics in a research note on Sunday, July 17th. Jefferies Group set a $58.00 price target on shares of Sarepta Therapeutics and gave the company a hold rating in a research note on Sunday. Robert W. Baird reaffirmed a buy rating on shares of Sarepta Therapeutics in a research note on Friday, June 10th. Janney Montgomery Scott reaffirmed a hold rating on shares of Sarepta Therapeutics in a research note on Tuesday, June 7th. Finally, WBB Securities reaffirmed a buy rating and set a $40.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, June 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $58.12.
Sarepta Therapeutics (NASDAQ:SRPT) traded down 0.02% during trading on Wednesday, hitting $62.34. The stock had a trading volume of 278,178 shares. The company has a 50-day moving average of $39.01 and a 200 day moving average of $24.87. The firm’s market cap is $2.99 billion. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $63.73.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the company earned ($0.87) EPS. On average, equities research analysts predict that Sarepta Therapeutics will post ($4.16) earnings per share for the current fiscal year.
In other Sarepta Therapeutics news, VP Jayant Aphale sold 35,000 shares of Sarepta Therapeutics stock in a transaction on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $1,750,000.00. Following the transaction, the vice president now directly owns 21,490 shares in the company, valued at $1,074,500. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP David T. Howton sold 7,000 shares of Sarepta Therapeutics stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total transaction of $420,000.00. Following the completion of the transaction, the senior vice president now owns 28,453 shares in the company, valued at $1,707,180. The disclosure for this sale can be found here. 10.90% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. Teacher Retirement System of Texas raised its position in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares in the last quarter. Advisor Group Inc. purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at $154,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at $211,000. BNP Paribas Arbitrage SA increased its stake in shares of Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock valued at $217,000 after buying an additional 1,886 shares during the last quarter. Finally, National Planning Corp increased its stake in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the last quarter. Institutional investors own 65.29% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.